Karyopharm Therapeutics

Fierce Biotech Layoff Tracker 2023: Bayer-bought BlueRock makes cuts; Alaunos lets go 60% of teams
Fierce Biotech
Fri, 08/18/23 - 10:28 am
layoffs
Alaunos Therapeutics
BlueRock Therapeutics
Thermo Fisher
Bristol Myers Squibb
Atreca
Galera Therapeutics
Inovio
Salarius Pharmaceuticals
Karyopharm Therapeutics
Intergalatic Therapeutics
Karyopharm cuts staff amid push to broaden use of blood cancer drug
BioPharma Dive
Wed, 08/2/23 - 10:38 pm
Karyopharm Therapeutics
layoffs
Xpovio
Biogen Halts ALS Asset Agreement with Karyopharm
BioSpace
Thu, 06/16/22 - 10:25 am
Biogen
Karyopharm Therapeutics
ALS
KPT-350
FDA sets back Karyopharm's bid to broaden use of cancer drug
BioPharma Dive
Wed, 03/2/22 - 12:08 pm
Karyopharm Therapeutics
Selinexor
clinical trials
FDA
cancer
Fortunes diverge for solo drug launchers
EP Vantage
Tue, 05/11/21 - 11:01 am
drug launches
Intra-Cellular Therapies
Biocryst
Horizon Therapeutics
Karyopharm Therapeutics
Blueprint Medicines
Zogenix
Esperion
Epizyme
Aurinia Pharmaceuticals
Global Blood Therapeutics
Karyopharm spotlights PhIII results after controversial FDA approval
Endpoints
Mon, 03/2/20 - 11:01 am
Karyopharm Therapeutics
Xpovio
FDA
clinical trials
Mass exodus of Amgen sales reps sparks legal battle with multiple myeloma rival Karyopharm
Fierce Pharma
Fri, 05/24/19 - 04:35 pm
Amgen
sales poaching
drug reps
Karyopharm Therapeutics
Multiple Myeloma
Selinexor
ODAC backs delay for Karyopharm’s selinexor
BioCentury
Tue, 02/26/19 - 11:43 pm
Karyopharm Therapeutics
ODAC
Selinexor
Karyopharm down as FDA reviewers cast doubt on selinexor's benefit
BioCentury
Sat, 02/23/19 - 04:35 pm
Karyopharm Therapeutics
FDA
Selinexor
Multiple Myeloma
Karyopharm to pursue FDA approval for multiple myeloma drug based on new study results
Stat
Mon, 04/30/18 - 07:33 pm
Karyopharm Therapeutics
FDA
Multiple Myeloma
Selinexor
clinical trials
This Week in Biotech: Clinical Success, Plus Wheeling and Dealing
Motley Fool
Sun, 01/26/14 - 10:46 am
BioDelivery Sciences
Endo Health Solutions
Karyopharm Therapeutics
Repligen
Biomarin
Ariad Pharmaceuticals
Eli Lilly
GSK
Shire